WEBULL
News
XNCR
18.14
+4.79%
0.83
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC)
TipRanks · 2d ago
Weekly Report: what happened at XNCR last week (1124-1128)?
Weekly Report · 4d ago
Xencor Initiated at Buy by Truist Securities
Dow Jones · 11/24 18:14
Xencor initiated with a Buy at Truist
TipRanks · 11/24 12:20
Weekly Report: what happened at XNCR last week (1117-1121)?
Weekly Report · 11/24 09:05
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Reuters · 11/24 08:05
Weekly Report: what happened at XNCR last week (1110-1114)?
Weekly Report · 11/17 09:05
Xencor Inc. to Present at TD Cowen Immunology and Inflammation Virtual Summit
Reuters · 11/10 21:01
Weekly Report: what happened at XNCR last week (1103-1107)?
Weekly Report · 11/10 09:05
Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target
TipRanks · 11/07 13:47
RBC Capital Keeps Their Buy Rating on Xencor (XNCR)
TipRanks · 11/07 01:49
Xencor Price Target Cut to $18.00/Share From $20.00 by JP Morgan
Dow Jones · 11/06 22:49
Xencor Is Maintained at Overweight by JP Morgan
Dow Jones · 11/06 22:49
JP Morgan Maintains Overweight on Xencor, Lowers Price Target to $18
Benzinga · 11/06 22:39
Xencor Is Maintained at Outperform by RBC Capital
Dow Jones · 11/06 16:42
Xencor Price Target Raised to $19.00/Share From $18.00 by RBC Capital
Dow Jones · 11/06 16:42
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $19
Benzinga · 11/06 16:31
Xencor (XNCR) Gets a Hold from Bank of America Securities
TipRanks · 11/06 15:19
Xencor Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 11/06 15:02
Xencor Price Target Raised to $42.00/Share From $40.00 by Cantor Fitzgerald
Dow Jones · 11/06 15:02
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.